{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:11:10Z","timestamp":1788480670836,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50760-9","type":"journal-article","created":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:01:42Z","timestamp":1722733302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9895","authenticated-orcid":false,"given":"Marieke","family":"van der Heiden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-9915","authenticated-orcid":false,"given":"Sudarshan","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Bijvank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6123-9830","authenticated-orcid":false,"given":"Alper","family":"Cevirgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"van Sleen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tcherniaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Ollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wivine","family":"Burny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.","family":"van Binnendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne A.","family":"van Houten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke Y.","family":"Rots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7735-9359","authenticated-orcid":false,"given":"Josine","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"van Baarle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,4]]},"reference":[{"key":"50760_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"50760_CR2","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2468-2667(19)30019-2","volume":"4","author":"AY Chang","year":"2019","unstructured":"Chang, A. Y., Skirbekk, V. F., Tyrovolas, S., Kassebaum, N. J. & Dieleman, J. L. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health 4, e159\u2013e167 (2019).","journal-title":"Lancet Public Health"},{"key":"50760_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nri3085","volume":"11","author":"R Rappuoli","year":"2015","unstructured":"Rappuoli, R., Mandl, C. W., Black, S. & De Gregorio, E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 11, 865\u2013872 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"50760_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14760584.2021.1880328","volume":"20","author":"MS Niederman","year":"2021","unstructured":"Niederman, M. S. et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev. Vaccines 20, 243\u2013256 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"50760_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/vaccines10091480","volume":"10","author":"LL van den Hoogen","year":"2022","unstructured":"van den Hoogen, L. L. et al. Reduced antibody acquisition with increasing age following vaccination with BNT162b2: results from two longitudinal cohort studies in The Netherlands. Vaccines 10, 1480 (2022).","journal-title":"Vaccines"},{"key":"50760_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"50760_CR7","doi-asserted-by":"crossref","unstructured":"Kimball, J., Zhu, Y., Wyatt, D., Trabue, C. H. & Talbot, H. K. Influenza vaccine failure associated with age and immunosuppression. J. Infect. Dis. 224, 288\u2013293 (2020).","DOI":"10.1093\/infdis\/jiaa757"},{"key":"50760_CR8","doi-asserted-by":"publisher","first-page":"2045857","DOI":"10.1080\/21645515.2022.2045857","volume":"18","author":"E Nanishi","year":"2022","unstructured":"Nanishi, E., Levy, O. & Ozonoff, A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum. Vaccines Immunother. 18, 2045857 (2022).","journal-title":"Hum. Vaccines Immunother."},{"key":"50760_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-020-00181-1","volume":"17","author":"JE McElhaney","year":"2020","unstructured":"McElhaney, J. E. et al. The immune response to influenza in older humans: Beyond immune senescence. Immun. Ageing 17, 1\u201310 (2020).","journal-title":"Immun. Ageing"},{"key":"50760_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/acel.13703","volume":"21","author":"A Cevirgel","year":"2022","unstructured":"Cevirgel, A. et al. Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation. Aging Cell 21, 1\u201314 (2022).","journal-title":"Aging Cell"},{"key":"50760_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0167-5699(97)01145-6","volume":"18","author":"G Pawelec","year":"1997","unstructured":"Pawelec, G. & Solana, R. Immunosenescence. Immunol. Today 18, 514\u2013516 (1997).","journal-title":"Immunol. Today"},{"key":"50760_CR12","doi-asserted-by":"publisher","first-page":"111357","DOI":"10.1016\/j.mad.2020.111357","volume":"192","author":"G Pawelec","year":"2020","unstructured":"Pawelec, G. et al. The conundrum of human immune system \u201csenescence\u201d. Mech. Ageing Dev. 192, 111357 (2020).","journal-title":"Mech. Ageing Dev."},{"key":"50760_CR13","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop, T. et al. Immunosenescence and inflamm-aging as two sides of the same coin: Friends or Foes? Front. Immunol. 8, 1960 (2018).","journal-title":"Front. Immunol."},{"key":"50760_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1742-4933-10-20","volume":"10","author":"C Caruso","year":"2013","unstructured":"Caruso, C., Accardi, G., Virruso, C. & Candore, G. Sex, gender and immunosenescence: a key to understand the different lifespan between men and women? Immun. Ageing 10, 20 (2013).","journal-title":"Immun. Ageing"},{"key":"50760_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3389\/fimmu.2018.01269","volume":"9","author":"MRG Bupp","year":"2018","unstructured":"Bupp, M. R. G., Potluri, T., Fink, A. L. & Klein, S. L. The confluence of sex hormones and aging on immunity. Front. Immunol. 9, 1269 (2018).","journal-title":"Front. Immunol."},{"key":"50760_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","volume":"160","author":"P Brodin","year":"2015","unstructured":"Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37\u201347 (2015).","journal-title":"Cell"},{"key":"50760_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10654-021-00767-z","volume":"36","author":"J Goudsmit","year":"2021","unstructured":"Goudsmit, J. et al. Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program. Eur. J. Epidemiol. 36, 753\u2013762 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"50760_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40520-018-0936-7","volume":"31","author":"G Rubino","year":"2019","unstructured":"Rubino, G. et al. Sicilian centenarian offspring are more resistant to immune ageing. Aging Clin. Exp. Res. 31, 125\u2013133 (2019).","journal-title":"Aging Clin. Exp. Res."},{"key":"50760_CR19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","volume":"394","author":"EO Hoogendijk","year":"2019","unstructured":"Hoogendijk, E. O. et al. Frailty: implications for clinical practice and public health. Lancet 394, 1365\u20131375 (2019).","journal-title":"Lancet"},{"key":"50760_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2318-8-24","volume":"8","author":"SD Searle","year":"2008","unstructured":"Searle, S. D., Mitnitski, A., Gahbauer, E. A., Gill, T. M. & Rockwood, K. A standard procedure for creating a frailty index. BMC Geriatr. 8, 24 (2008).","journal-title":"BMC Geriatr."},{"key":"50760_CR21","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1016\/j.vaccine.2020.07.005","volume":"38","author":"D Van Baarle","year":"2020","unstructured":"Van Baarle, D. et al. Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project. Vaccine 38, 5896\u20135904 (2020).","journal-title":"Vaccine"},{"key":"50760_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/vaccines11071201","volume":"11","author":"S Haggenburg","year":"2023","unstructured":"Haggenburg, S. et al. Immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia. Vaccines 11, 1201 (2023).","journal-title":"Vaccines"},{"key":"50760_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1128\/CVI.00735-14","volume":"22","author":"TM Daly","year":"2015","unstructured":"Daly, T. M. & Hill, H. R. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin. Vaccin. Immunol. 22, 148\u2013152 (2015).","journal-title":"Clin. Vaccin. Immunol."},{"key":"50760_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","volume":"130","author":"JS Orange","year":"2012","unstructured":"Orange, J. S. et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J. Allergy Clin. Immunol. 130, S1\u2013S24 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"50760_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40266-018-0597-4","volume":"36","author":"MK Andrew","year":"2019","unstructured":"Andrew, M. K. et al. Influenza vaccination in older adults: recent innovations and practical applications. Drugs Aging 36, 29\u201337 (2019).","journal-title":"Drugs Aging"},{"key":"50760_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/CIA.S25215","volume":"7","author":"PO Lang","year":"2012","unstructured":"Lang, P. O. et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin. Inter. Aging 7, 55\u201364 (2012).","journal-title":"Clin. Inter. Aging"},{"key":"50760_CR27","doi-asserted-by":"publisher","first-page":"103998","DOI":"10.1016\/j.cellimm.2019.103998","volume":"348","author":"HL Dugan","year":"2020","unstructured":"Dugan, H. L., Henry, C. & Wilson, P. C. Aging and influenza vaccine-induced immunity. Cell. Immunol. 348, 103998 (2020).","journal-title":"Cell. Immunol."},{"key":"50760_CR28","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.3390\/ijerph16224489","volume":"16","author":"M Ganczak","year":"2019","unstructured":"Ganczak, M. et al. Quadrivalent influenza vaccine-induced antibody response and influencing determinants in patients \u2265 55 years of age in the 2018\/2019 season. Int. J. Environ. Res. Public Health 16, 4489 (2019).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"50760_CR29","unstructured":"World Health Organization. Addendum to the Recommended Composition of Influenza Virus Vaccines for Use in the 2019-2020 Northern Hemisphere Season (2019)."},{"key":"50760_CR30","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/v13091786","volume":"13","author":"JA Gaevert","year":"2021","unstructured":"Gaevert, J. A., Duque, D. L., Lythe, G., Molina-Par\u00eds, C. & Thomas, P. G. Quantifying t cell cross-reactivity: Influenza and coronaviruses. Viruses 13, 1786 (2021).","journal-title":"Viruses"},{"key":"50760_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41577-019-0180-1","volume":"19","author":"JJ Goronzy","year":"2019","unstructured":"Goronzy, J. J. & Weyand, C. M. Mechanisms underlying T cell ageing. Nat. Rev. Immunol. 19, 573\u2013583 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"50760_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/erv.11.187","volume":"11","author":"PO Lang","year":"2012","unstructured":"Lang, P. O. & Aspinall, R. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules? Expert Rev. Vaccines 11, 167\u2013176 (2012).","journal-title":"Expert Rev. Vaccines"},{"key":"50760_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-018-0001-y","volume":"18","author":"T Van Den Broek","year":"2018","unstructured":"Van Den Broek, T., Borghans, J. A. M., & Van Wijk, F. The full spectrum of human naive T cells. Nat. Rev. Immunol. 18, 363\u2013373 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"50760_CR34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.immuni.2012.02.006","volume":"36","author":"I den Braber","year":"2012","unstructured":"den Braber, I. et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 36, 288\u2013297 (2012).","journal-title":"Immunity"},{"key":"50760_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01618","volume":"9","author":"ES Egorov","year":"2018","unstructured":"Egorov, E. S. et al. The changing landscape of naive T cell receptor repertoire with human aging. Front. Immunol. 9, 1\u201312 (2018).","journal-title":"Front. Immunol."},{"key":"50760_CR36","doi-asserted-by":"publisher","first-page":"778679","DOI":"10.3389\/fimmu.2021.778679","volume":"12","author":"J Demaret","year":"2021","unstructured":"Demaret, J. et al. Impaired functional T-cell response to SARS-CoV-2 after two doses of BNT162b2 mRNA vaccine in older people. Front. Immunol. 12, 778679 (2021).","journal-title":"Front. Immunol."},{"key":"50760_CR37","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/cid\/civ686","volume":"61","author":"CH Van Werkhoven","year":"2015","unstructured":"Van Werkhoven, C. H., Huijts, S. M., Bolkenbaas, M., Grobbee, D. E. & Bonten, M. J. M. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin. Infect. Dis. 61, 1835\u20131838 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"50760_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1128\/IAI.00768-10","volume":"79","author":"S Park","year":"2011","unstructured":"Park, S. & Nahm, M. H. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect. Immun. 79, 314\u2013320 (2011).","journal-title":"Infect. Immun."},{"key":"50760_CR39","doi-asserted-by":"publisher","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","volume":"6","author":"AH Roukens","year":"2011","unstructured":"Roukens, A. H. et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS ONE 6, e27753 (2011).","journal-title":"PLoS ONE"},{"key":"50760_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28111-8","volume":"8","author":"A Wagner","year":"2018","unstructured":"Wagner, A. et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci. Rep. 8, 9825 (2018).","journal-title":"Sci. Rep."},{"key":"50760_CR41","doi-asserted-by":"publisher","first-page":"e0194823","DOI":"10.1371\/journal.pone.0194823","volume":"13","author":"M Vissers","year":"2018","unstructured":"Vissers, M. et al. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS ONE 13, e0194823 (2018).","journal-title":"PLoS ONE"},{"key":"50760_CR42","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1002\/chem.201603599","volume":"23","author":"F Khatun","year":"2017","unstructured":"Khatun, F., Stephenson, R. J. & Toth, I. An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity. Chem. A Eur. J. 23, 4233\u20134254 (2017).","journal-title":"Chem. A Eur. J."},{"key":"50760_CR43","unstructured":"Dutch National Institute of Public Health and the Environment. The National Immunisation Programme in the Netherlands. Surveillance and Developments in 2022\u20132023 (2023)."},{"key":"50760_CR44","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/eji.201444878","volume":"45","author":"T Pritz","year":"2015","unstructured":"Pritz, T. et al. Plasma cell numbers decrease in bone marrow of old patients. Eur. J. Immunol. 45, 738\u2013746 (2015).","journal-title":"Eur. J. Immunol."},{"key":"50760_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","volume":"38","author":"MP Cancro","year":"2020","unstructured":"Cancro, M. P. Age-associated B cells. Annu. Rev. Immunol. 38, 315\u2013340 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"50760_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111613","volume":"41","author":"AR Burton","year":"2022","unstructured":"Burton, A. R. et al. The memory B cell response to influenza vaccination is impaired in older persons. Cell Rep. 41, 111613 (2022).","journal-title":"Cell Rep."},{"key":"50760_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri2508","volume":"9","author":"CA Siegrist","year":"2009","unstructured":"Siegrist, C. A. & Aspinall, R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9, 185\u2013194 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"50760_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.exger.2017.12.014","volume":"105","author":"M van der Heiden","year":"2018","unstructured":"van der Heiden, M. et al. Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: role of IgM. Exp. Gerontol. 105, 101\u2013108 (2018).","journal-title":"Exp. Gerontol."},{"key":"50760_CR49","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fimmu.2017.00817","volume":"8","author":"M van der Heiden","year":"2017","unstructured":"van der Heiden, M. et al. Novel intervention in the aging population: a primary meningococcal vaccine inducing protective IgM responses in middle-aged adults. Front. Immunol. 8, 817 (2017).","journal-title":"Front. Immunol."},{"key":"50760_CR50","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3389\/fimmu.2017.01962","volume":"8","author":"M van der Heiden","year":"2018","unstructured":"van der Heiden, M. et al. An explorative biomarker study for vaccine responsiveness after a primary meningococcal vaccination in middle-aged adults. Front. Immunol. 8, 1962 (2018).","journal-title":"Front. Immunol."},{"key":"50760_CR51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","volume":"10","author":"SL Klein","year":"2010","unstructured":"Klein, S. L., Jedlicka, A. & Pekosz, A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 10, 338\u2013349 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"50760_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14396-9","volume":"11","author":"EJ M\u00e1rquez","year":"2020","unstructured":"M\u00e1rquez, E. J. et al. Sexual-dimorphism in human immune system aging. Nat. Commun. 11, 751 (2020).","journal-title":"Nat. Commun."},{"key":"50760_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-4933-10-19","volume":"10","author":"K Hirokawa","year":"2013","unstructured":"Hirokawa, K. et al. Slower immune system aging in women versus men in the Japanese population. Immun. Ageing 10, 19 (2013).","journal-title":"Immun. Ageing"},{"key":"50760_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep26892","volume":"6","author":"M Van Der Heiden","year":"2016","unstructured":"Van Der Heiden, M. et al. Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. Sci. Rep. 6, 26892 (2016).","journal-title":"Sci. Rep."},{"key":"50760_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00412-6","volume":"6","author":"JR Shapiro","year":"2021","unstructured":"Shapiro, J. R. et al. Sex-specific effects of aging on humoral immune responses to repeated influenza vaccination in older adults. NPJ Vaccines 6, 147 (2021).","journal-title":"NPJ Vaccines"},{"key":"50760_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12979-023-00382-4","volume":"20","author":"Y Kuijpers","year":"2023","unstructured":"Kuijpers, Y. et al. Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study. Immun. Ageing 20, 57 (2023).","journal-title":"Immun. Ageing"},{"key":"50760_CR57","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"50760_CR58","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","volume":"28","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 28, 1072\u20131082 (2022).","journal-title":"Nat. Med."},{"key":"50760_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/v14040797","volume":"14","author":"P Kaaijk","year":"2022","unstructured":"Kaaijk, P. et al. Contribution of influenza viruses, other respiratory viruses and viral co-infections to influenza-like illness in older adults. Viruses 14, 797 (2022).","journal-title":"Viruses"},{"key":"50760_CR60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jix268","volume":"216","author":"J Van Beek","year":"2017","unstructured":"Van Beek, J. et al. Influenza-like illness incidence is not reduced by influenza vaccination in a cohort of older adults, despite effectively reducing laboratory-confirmed influenza virus infections. J. Infect. Dis. 216, 415\u2013424 (2017).","journal-title":"J. Infect. Dis."},{"key":"50760_CR61","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1016\/j.vaccine.2012.05.060","volume":"30","author":"W Luytjes","year":"2012","unstructured":"Luytjes, W. et al. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains. Vaccine 30, 5262\u20135269 (2012).","journal-title":"Vaccine"},{"key":"50760_CR62","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3389\/fimmu.2018.03103","volume":"9","author":"SK Rosendahl Huber","year":"2018","unstructured":"Rosendahl Huber, S. K. et al. Immunogenicity of influenza vaccines: evidence for differential effect of secondary vaccination on humoral and cellular immunity. Front. Immunol. 9, 3103 (2018).","journal-title":"Front. Immunol."},{"key":"50760_CR63","unstructured":"ECDC. Immunity following influenza disease and administration of influenza vaccines. https:\/\/www.ecdc.europa.eu\/en\/seasonal-influenza\/prevention-and-control\/vaccines\/immunity (2018)."},{"key":"50760_CR64","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.vaccine.2010.11.054","volume":"29","author":"KEM Elberse","year":"2011","unstructured":"Elberse, K. E. M. et al. Seroprevalence of IgG antibodies against 13 vaccine Streptococcus pneumoniae serotypes in the Netherlands. Vaccine 29, 1029\u20131035 (2011).","journal-title":"Vaccine"},{"key":"50760_CR65","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/CVI.00408-09","volume":"17","author":"KEM Elberse","year":"2010","unstructured":"Elberse, K. E. M., Tcherniaeva, I., Berbers, G. A. M. & Schouls, L. M. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin. Vaccin. Immunol. 17, 674\u2013682 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"50760_CR66","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/infdis\/jiaa479","volume":"222","author":"G Den Hartog","year":"2020","unstructured":"Den Hartog, G. et al. SARS-CoV-2-specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J. Infect. Dis. 222, 1452\u20131461 (2020).","journal-title":"J. Infect. Dis."},{"key":"50760_CR67","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12979-023-00391-3","volume":"20","author":"Y van Sleen","year":"2023","unstructured":"van Sleen, Y. et al. Frailty is related to serum inflammageing markers: results from the VITAL study. Immun. Ageing 20, 68 (2023).","journal-title":"Immun. Ageing"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50760-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T05:03:50Z","timestamp":1723007030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50760-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50760"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50760-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,4]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.O. and W.B. are employees of the GSK group of companies. W.B. holds shares in the GSK group of companies. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6603"}}